News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aegerion Pharmaceuticals, Inc. Comments on Standard Review Classification for Lomitapide NDA



3/8/2012 9:44:37 AM

CAMBRIDGE, Mass., March 8, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, today commented on U.S. Food and Drug Administration (FDA)'s standard review classification of Aegerion's New Drug Application (NDA) for its lead investigational therapeutic, lomitapide.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES